NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 244 shares, a decline of 50.5% from the December 31st total of 493 shares. Based on an average trading volume of 237 shares, the short-interest ratio is currently 1.0 days. Based on an average trading volume of 237 shares, the short-interest ratio is currently 1.0 days.
NewAmsterdam Pharma Stock Performance
NAMSW stock traded down $0.26 on Friday, hitting $19.61. 400 shares of the company were exchanged, compared to its average volume of 667. NewAmsterdam Pharma has a twelve month low of $5.45 and a twelve month high of $29.99. The business’s fifty day moving average is $24.26 and its two-hundred day moving average is $20.24.
Institutional Trading of NewAmsterdam Pharma
An institutional investor recently raised its stake in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC grew its holdings in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 245,000 shares of the company’s stock after purchasing an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent SEC filing.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Recommended Stories
- Five stocks we like better than NewAmsterdam Pharma
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
